

Zioptan[®] (tafluprost) – First-time authorized brand alternative

- On November 18, 2022, <u>Prasco launched</u> an authorized brand alternative (ABA) of Akorn's <u>Zioptan (tafluprost)</u> ophthalmic solution.
- Zioptan is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.